Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals a decline in revenue, increased expenses, and a substantial net loss, which are negative indicators. The Q&A session highlights uncertainties regarding FDA approval and payer engagement, further dampening sentiment. Despite robust clinical data, the lack of clear guidance on coverage and the need for additional funding for a full-scale launch contribute to a negative outlook. The absence of a new partnership announcement or positive financial metrics, coupled with the increased net loss and EBITDA loss, supports a negative stock price reaction.
Key Financial Performance
Total Revenue (Q2 2025) $10 million, a decrease from $20.1 million in Q2 2024. The decline was due to the onetime recognition of deferred revenue in the prior year. Excluding this, revenue increased by $0.3 million or 3% year-over-year, driven by growth in international products.
Manufacture and Supply Revenue (Q2 2025) $9.6 million, an increase from $8.1 million in Q2 2024. This growth was primarily due to increases in Ondif revenue, partially offset by decreases in Suboxone revenues.
Total Revenue (6 months ended June 30, 2025) $18.7 million, a decrease from $32.2 million for the same period in 2024. Excluding onetime recognition of deferred revenue, total revenues decreased by $2.8 million or 13% year-over-year, primarily due to decreases in Suboxone revenues.
Research and Development Expenses (6 months ended June 30, 2025) $9.5 million, a decrease from $10.1 million for the same period in 2024. The decline was primarily due to reduced clinical trial costs for the Anaphylm program, partially offset by increased personnel costs and share-based compensation.
Selling, General, and Administrative Expenses (Q2 2025) $12.7 million, an increase from $11.4 million in Q2 2024. The rise was driven by higher commercial spending for prelaunch activities ($2 million), regulatory and licensing fees ($0.8 million), personnel costs ($0.4 million), share-based compensation ($0.2 million), and consulting fees ($0.2 million), partially offset by lower legal fees ($2.5 million) and insurance expenses ($0.2 million).
Net Loss (Q2 2025) $13.5 million or $0.14 per share, compared to $2.7 million or $0.03 per share in Q2 2024. Excluding onetime recognition of deferred revenue, the net loss in Q2 2024 was $13.2 million.
Non-GAAP Adjusted EBITDA Loss (Q2 2025) $9.3 million, compared to $1.8 million income in Q2 2024. Excluding onetime recognition of deferred revenue, the adjusted EBITDA loss in Q2 2024 was $8.6 million.
Cash and Cash Equivalents (as of June 30, 2025) $60.5 million, sufficient for initial launch activities but requiring additional funding for full-scale launch.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Anaphylm epinephrine sublingual film: Potentially the first and only oral product for severe allergic reactions, including anaphylaxis. FDA action date is January 31, 2026. Pre-commercial launch activities and FDA review are on track. Pediatric study data included in the NDA submission. Market potential estimated at $2 billion annually globally.
AQST-108 epinephrine topical gel: Targeting alopecia areata. IND submission to FDA planned by end of 2025, with human studies starting in early 2026.
International expansion for Anaphylm: Meetings secured in Canada and EU for regulatory discussions. Filing preparations to begin after meetings by year-end.
Manufacturing and supply revenue: Increased to $9.6 million in Q2 2025 from $8.1 million in Q2 2024, driven by growth in Ondif, partially offset by Suboxone decline.
Base business growth: Year-over-year growth in Q2 2025, driven by international product performance.
Launch financing for Anaphylm: Multiple proposals in process, including EU-only rights and alternate financing vehicles. Confident in securing financing before launch.
Market access strategy for Anaphylm: Patient-first approach with a cash pay program to ensure immediate access despite payer barriers. Engaging with payers for pricing and reimbursement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Access Barriers: The company has expressed concerns about significant barriers to market access for their product Anaphylm, including pricing issues, delay tactics, NDC blocks, and prior authorization documentation. These barriers could increase costs and limit patient access to the product.
Launch Financing Challenges: Aquestive Therapeutics has acknowledged the need for additional funding to support the commercial launch of Anaphylm. While they are exploring multiple financing options, the lack of secured funding poses a risk to the timely and effective launch of the product.
Regulatory Uncertainty: The company is awaiting FDA approval for Anaphylm, with a PDUFA action date set for January 31, 2026. Any delays or negative outcomes in the regulatory process could adversely impact their strategic plans.
Revenue Decline: The company has reported a decline in total revenues year-over-year, primarily due to the decrease in Suboxone revenues. This decline could affect their financial stability and ability to fund future projects.
Increased Operating Costs: Selling, general, and administrative expenses have increased significantly due to prelaunch activities, regulatory fees, and personnel costs. This rise in costs could strain the company's financial resources.
Dependence on Key Product Approval: The company's future growth heavily depends on the approval and successful launch of Anaphylm. Any setbacks in this area could have a significant negative impact on their operations and financials.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
FDA Approval and Launch of Anaphylm: Aquestive Therapeutics is on track for the FDA action date for Anaphylm, scheduled for January 31, 2026. The company is preparing for a potential advisory committee meeting and has completed its 120-day safety update submission. Pre-commercial launch activities are underway, and the company is securing launch financing.
Market Opportunity for Anaphylm: The rescue market for severe allergic reactions is expected to grow significantly, potentially doubling from 5 million to 10 million prescriptions annually. The market could reach $2 billion globally, with a shift from injectables to non-injectable products like Anaphylm.
International Expansion: Meetings with regulatory bodies in Canada and the EU are planned by the end of 2025 to prepare for international filings for Anaphylm.
Launch Financing: Aquestive is exploring multiple financing options, including EU-only rights and alternative financing vehicles, to support the launch of Anaphylm. The company expects to secure financing before the product launch.
Future Product Development: The company plans to open an IND for AQST-108, an epinephrine topical gel for alopecia areata, by the end of 2025 and begin human studies in early 2026.
2025 Financial Guidance: Aquestive expects total revenue of $44 million to $50 million and a non-GAAP adjusted EBITDA loss of $47 million to $51 million for 2025. This includes significant pre-approval launch spending for Anaphylm.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you provide details on the likelihood of an FDA Ad Comm meeting and your confidence in the clinical data package?
A:The likelihood of an Ad Comm meeting remains uncertain, as the FDA has not indicated a decision yet. The company expects to know within weeks to a month. The clinical data package is robust, consisting of 10 studies, over 930 exposures, and 350 subjects, which the management believes addresses all potential FDA questions.
Q:Can you discuss out-of-pocket exposure for patients, payer landscape, and cash pay initiatives?
A:Discussions with payers are ongoing but limited to awareness due to pre-approval restrictions. Out-of-pocket concerns are industry-wide, not specific to the nasal spray. Cash pay is expected to be a significant part of the market, with its importance likely growing over time. Co-pay buy-down programs will be balanced and part of the strategy.
Q:Have you reviewed former CRLs and Ad Comm experiences of competitors, and what have you learned?
A:Yes, the company has reviewed these documents. The key learning is to adhere closely to FDA requirements. For example, the company included a repeat dose arm in their oral allergy syndrome study, addressing FDA's specific requests.
Q:Can you provide more details on the pediatric study and its safety profile?
A:The pediatric study focused on characterizing the PK profile, showing comparable results to adult studies. Safety outcomes were consistent with no significant differences in character, frequency, or severity of adverse events.
Q:Has there been any substantial data analysis or information requests from the FDA during the review?
A:No major data requests have been made beyond the standard 120-day safety update. The company has had usual back-and-forth interactions with the FDA.
Q:What work has been done to increase awareness of Anaphylm?
A:The company has conducted CME and non-CME activities, published posters, and participated in conferences. Feedback from the allergy community has been positive, with HCPs believing the product will improve carry rates and reduce barriers to use.
Q:What is the business development strategy for Anaphylm in ex-U.S. territories, and how does pricing fit into this?
A:The company is open to partnerships to maximize patient access. Ex-U.S. pricing and most favored nation policies are not expected to significantly impact the rescue market due to its lower price point and non-chronic nature.
Q:What does the ideal physician prescriber of Anaphylm look like, and are you confident in achieving 80% coverage within six months of launch?
A:The ideal prescriber is an allergist, who typically prescribes 200+ prescriptions annually. The company is confident in achieving broad coverage competitive with other products, though the 80% mark is not guaranteed.
Q:Have you conducted post-launch patient research to understand what drives patients to fill prescriptions for needle-free alternatives?
A:Patients prioritize choice, ease of use, and portability. Physicians and moms (as decision-makers) value products that are easy to carry and use. Competitor direct-to-consumer education has increased awareness, benefiting the overall rescue market.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer on the likelihood of achieving 80% coverage within six months of launch, stating general confidence in broad coverage but not committing to the specific target.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AQST epinephrine
Advisory Committee
Alimohamed Leerink
Allergy Asthma
Americans anaphylaxis
Americans coverage
Amsellem
Anaphylm FDA
Anaphylm patient
Chief Commercial
Co Research
Commercial Officer
Conference
EU
FDA review
Inc Research
LLC Research
QA session
Research Division
action date
barrier
health care
injectables
item
launch financing
patient caregiver
point
pricing
process Anaphylm
product market
safety update
track launch
update FDA
AQST Transcript
Aquestive Therapeutics, Inc. (AQST) Q1 2026 Earnings Call Transcript
Positive5-14
The earnings call summary and Q&A reveal strong financial performance, strategic product development, and promising market strategies. Anaphylm's launch preparation and international expansion plans are positive indicators, supported by stable financials and a robust cash position. The Q&A highlights management's proactive approach to market challenges and confidence in regulatory timelines, despite some uncertainties. Overall, the company's strategic initiatives and financial health suggest a positive stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q4 2025 Earnings Call Transcript
Unknown3-5
The earnings call presents a mixed outlook. The FDA approval and launch of Anaphylm, along with international expansion plans, suggest potential growth. However, financial guidance shows a significant EBITDA loss, and there are uncertainties regarding FDA meetings and protocol modifications. The Q&A reveals positive sentiment from the allergist community and readiness for regulatory requirements, but management's vague responses on certain issues raise concerns. Overall, the combination of positive development plans and financial challenges results in a neutral sentiment.
Aquestive Therapeutics, Inc. (AQST) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call summary presents a mixed outlook. Positive aspects include the FDA approval track for Anaphylm, international expansion plans, and new patents. However, financial guidance indicates a significant EBITDA loss, and management was vague on pricing and partnerships. The Q&A revealed cautious optimism but also highlighted uncertainties, such as pricing and international strategies. Considering these factors, the overall sentiment is neutral, anticipating limited stock price movement.
Aquestive Therapeutics, Inc. (AQST) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call reveals a decline in revenue, increased expenses, and a substantial net loss, which are negative indicators. The Q&A session highlights uncertainties regarding FDA approval and payer engagement, further dampening sentiment. Despite robust clinical data, the lack of clear guidance on coverage and the need for additional funding for a full-scale launch contribute to a negative outlook. The absence of a new partnership announcement or positive financial metrics, coupled with the increased net loss and EBITDA loss, supports a negative stock price reaction.
AQST Slides
AQST Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
